OBJECTIVE: To investigate the relationship of the time interval from the completion of neoadjuvant chemotherapy (NAC) to the initiation of postoperative adjuvant chemotherapy (POAC) with the survival outcomes in patients with ovarian cancer. METHODS: We retrospectively investigated 220 patients with pathologically confirmed epithelial ovarian cancer who received NAC at Yonsei Cancer Hospital between 2006 and 2016. The time interval was defined as the period from the completion of NAC, spanning interval debulking surgery (IDS), to the initiation of POAC. RESULTS: The median time interval was 42 (range 16-178) days; 103 patients (53.1%) received POAC within 42days after NAC while 91 patients (46.9%) received it after 42days. There wer...
OBJECTIVES: Complete surgery with no macroscopic residual disease (RD) at primary (PDS) or interval ...
ObjectivesTo compare clinical outcomes for stage IIIC and IV ovarian cancer patients receiving neoad...
Objective: Neoadjuvant chemotherapy plus interval debulking surgery is growing treatment strategy fo...
OBJECTIVE: Treatment for advanced epithelial ovarian cancer (EOC) consists of debulking surgery and ...
Purpose: Optimal cytoreduction (CRS) is the main treatment modality in epithelial ovarian cancer (OC...
Abstract Background To investigate the prognostic relevance of the time to interval debulking surger...
Objectives: Clinicians often question when to start chemotherapy after patients undergo surgery for ...
Background: We evaluated the impact of neoadjuvant chemotherapy (NC) relative to primary surgery (PS...
Aim: The optimal number of neoadjuvant chemotherapy (NACT) cycles is unclear in epithelial ovarian c...
Objectives: Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) may be a va...
Hao Lin,1 Wen-Hsin Chen,1 Chen-Hsuan Wu,1,2 Yu-Che Ou,3 Yu-Jen Chen,3 Ying-Yi Chen,1 Yu-Han Lin,4 Hu...
Contains fulltext : 193307.pdf (publisher's version ) (Closed access)INTRODUCTION:...
Objective. Cytoreductive surgery and platinum-based systemic therapy constitute the standard treatme...
OBJECTIVE:We aimed to investigate the prognostic impact of duration of first-line chemotherapy admin...
International audienceObjective. Interval debulking surgery is recommended after 3–4 cycles (standar...
OBJECTIVES: Complete surgery with no macroscopic residual disease (RD) at primary (PDS) or interval ...
ObjectivesTo compare clinical outcomes for stage IIIC and IV ovarian cancer patients receiving neoad...
Objective: Neoadjuvant chemotherapy plus interval debulking surgery is growing treatment strategy fo...
OBJECTIVE: Treatment for advanced epithelial ovarian cancer (EOC) consists of debulking surgery and ...
Purpose: Optimal cytoreduction (CRS) is the main treatment modality in epithelial ovarian cancer (OC...
Abstract Background To investigate the prognostic relevance of the time to interval debulking surger...
Objectives: Clinicians often question when to start chemotherapy after patients undergo surgery for ...
Background: We evaluated the impact of neoadjuvant chemotherapy (NC) relative to primary surgery (PS...
Aim: The optimal number of neoadjuvant chemotherapy (NACT) cycles is unclear in epithelial ovarian c...
Objectives: Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) may be a va...
Hao Lin,1 Wen-Hsin Chen,1 Chen-Hsuan Wu,1,2 Yu-Che Ou,3 Yu-Jen Chen,3 Ying-Yi Chen,1 Yu-Han Lin,4 Hu...
Contains fulltext : 193307.pdf (publisher's version ) (Closed access)INTRODUCTION:...
Objective. Cytoreductive surgery and platinum-based systemic therapy constitute the standard treatme...
OBJECTIVE:We aimed to investigate the prognostic impact of duration of first-line chemotherapy admin...
International audienceObjective. Interval debulking surgery is recommended after 3–4 cycles (standar...
OBJECTIVES: Complete surgery with no macroscopic residual disease (RD) at primary (PDS) or interval ...
ObjectivesTo compare clinical outcomes for stage IIIC and IV ovarian cancer patients receiving neoad...
Objective: Neoadjuvant chemotherapy plus interval debulking surgery is growing treatment strategy fo...